Circulating metabolites in the early stage of breast cancer were not related to cancer stage or subtypes but associated with ki67 level. Promising statistical discrimination from controls

Baranovičová, Eva; Račay, Peter; Žúbor, Pavol; Smolár, Marek; Kudelova, Eva; Halašová, Erika; Dvorska, Dana; Daňková, Zuzana

doi:10.1016/j.mcp.2022.101862

Cited by 7 publications

(11 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 481 Eva et al had profiled serum metabolite signatures in early breast cancer participants and found that circulating metabolites: glutamine, tyrosine, proline, histidine, alanine and citrate can significantly correlate with tumor proliferation. 482 Interestingly, a panel of two potential predictive metabolites (palmitic amide and deoxycholic acid) in serum was reported as potential biomarker of Crohn’s disease patients, and its metabolic disturbance involved the fatty acids, bile acid biosynthesis, and energy metabolism. 483 Additionally with the use of correlation analysis and ROC curve analysis, the characteristic metabolites including alanine, glucose, lactate, glycine and threonine were identified in pulmonary arterial hypertension patients, and threonine and lactate were markedly correlated with pulmonary vascular resistance and arterial pressure.…”

Section: Promising Biomarkersmentioning

confidence: 99%

Small molecule metabolites: discovery of biomarkers and therapeutic targets

Qiu

Cai

et al. 2023

Sig Transduct Target Ther

234

View full text Add to dashboard Cite

Metabolic abnormalities lead to the dysfunction of metabolic pathways and metabolite accumulation or deficiency which is well-recognized hallmarks of diseases. Metabolite signatures that have close proximity to subject’s phenotypic informative dimension, are useful for predicting diagnosis and prognosis of diseases as well as monitoring treatments. The lack of early biomarkers could lead to poor diagnosis and serious outcomes. Therefore, noninvasive diagnosis and monitoring methods with high specificity and selectivity are desperately needed. Small molecule metabolites-based metabolomics has become a specialized tool for metabolic biomarker and pathway analysis, for revealing possible mechanisms of human various diseases and deciphering therapeutic potentials. It could help identify functional biomarkers related to phenotypic variation and delineate biochemical pathways changes as early indicators of pathological dysfunction and damage prior to disease development. Recently, scientists have established a large number of metabolic profiles to reveal the underlying mechanisms and metabolic networks for therapeutic target exploration in biomedicine. This review summarized the metabolic analysis on the potential value of small-molecule candidate metabolites as biomarkers with clinical events, which may lead to better diagnosis, prognosis, drug screening and treatment. We also discuss challenges that need to be addressed to fuel the next wave of breakthroughs.

show abstract

Section: Promising Biomarkersmentioning

confidence: 99%

Small molecule metabolites: discovery of biomarkers and therapeutic targets

Qiu

Cai

et al. 2023

Sig Transduct Target Ther

234

View full text Add to dashboard Cite

show abstract

“…Similarly, a number of studies have also noted an increase in the amino acid content compared to healthy controls [ 50 , 61 ]. According to other data, in patients with breast cancer, a decrease in the plasma levels of branched-chain amino acids (BCAAs) was observed [ 57 ]. Lai et al [ 62 ] showed that a decrease in the content of seven amino acids (Ala, His, Thr, Arg, Pro, Glu, and Gly) occurs more than six times more often than their increase.…”

Section: Diagnostic Value Of Determination Of Amino Acids In Biologic...mentioning

confidence: 99%

“…Jasby et al [ 6 ], using 30 metabolites, showed that AUC = 0.89 (95% CI: 0.85–0.93), sensitivity = 0.80, and specificity = 0.75. Baranovicova et al [ 57 ] showed that AUC > 0.91 for 10 metabolites, while only for the BCAAs, AUC = 0.733. Only for the combination of 10 amino acids, Han et al [ 58 ] showed that AUC = 0.91.…”

Section: Diagnostic Value Of Determination Of Amino Acids In Biologic...mentioning

confidence: 99%

“…Baranovicova et al [ 57 ] showed that the levels of circulating metabolites are not associated with breast cancer molecular subtypes (luminal A/luminal B), histological findings, or stage. According to the authors, in the early stage of breast cancer, patients have common metabolic fingerprints in blood plasma, regardless of the degree, stage, or molecular subtype of breast cancer.…”

Section: Diagnostic Value Of Determination Of Amino Acids In Biologic...mentioning

confidence: 99%

“…According to the authors, in the early stage of breast cancer, patients have common metabolic fingerprints in blood plasma, regardless of the degree, stage, or molecular subtype of breast cancer. However, statistically significant correlations were found between the level of tumor proliferation marker Ki-67 and circulating metabolites: Ala, Tyr, Gln, His, and Pro [ 57 ].…”

Section: Diagnostic Value Of Determination Of Amino Acids In Biologic...mentioning

confidence: 99%

See 2 more Smart Citations

The Role of Amino Acids in the Diagnosis, Risk Assessment, and Treatment of Breast Cancer: A Review

Bel’skaya,

Gundyrev,

Solomatin

2023

CIMB

View full text Add to dashboard Cite

This review summarizes the role of amino acids in the diagnosis, risk assessment, imaging, and treatment of breast cancer. It was shown that the content of individual amino acids changes in breast cancer by an average of 10–15% compared with healthy controls. For some amino acids (Thr, Arg, Met, and Ser), an increase in concentration is more often observed in breast cancer, and for others, a decrease is observed (Asp, Pro, Trp, and His). The accuracy of diagnostics using individual amino acids is low and increases when a number of amino acids are combined with each other or with other metabolites. Gln/Glu, Asp, Arg, Leu/Ile, Lys, and Orn have the greatest significance in assessing the risk of breast cancer. The variability in the amino acid composition of biological fluids was shown to depend on the breast cancer phenotype, as well as the age, race, and menopausal status of patients. In general, the analysis of changes in the amino acid metabolism in breast cancer is a promising strategy not only for diagnosis, but also for developing new therapeutic agents, monitoring the treatment process, correcting complications after treatment, and evaluating survival rates.

show abstract

Predictive analysis of breast cancer response to neoadjuvant chemotherapy through plasma metabolomics

Yamada,

Jinno,

Naruse

et al. 2024

Breast Cancer Res Treat

View full text Add to dashboard Cite

Preoperative chemotherapy is a critical component of breast cancer management, yet its effectiveness is not uniform. Moreover, the adverse effects associated with chemotherapy necessitate the identi cation of a patient subgroup that would derive the maximum bene t from this treatment. This study aimed to establish a method for predicting the response to preoperative chemotherapy in breast cancer patients utilizing metabolomics. MethodsPlasma samples were obtained from 87 breast cancer patients undergoing preoperative chemotherapy at our facility, collected both prior to the commencement of the treatment and before the second treatment cycle. Metabolite analysis was conducted using capillary electrophoresis-mass spectrometry (CE-MS) and liquid chromatography-mass spectrometry (LC-MS). We performed comparative pro ling of metabolite concentrations by assessing the metabolite pro les of patients who achieved a pathological complete response (pCR) against those who did not, both in initial and subsequent treatment cycles. ResultsSigni cant variances were observed in the metabolite pro les between pCR and non-pCR cases, both at the onset of preoperative chemotherapy and before the second cycle. Noteworthy distinctions were also evident between the metabolite pro les from the initial and the second preoperative chemotherapy courses. Furthermore, metabolite pro les exhibited variations associated with intrinsic subtypes at all assessed time points. ConclusionThe application of plasma metabolomics, utilizing CE-MS and LC-MS, has proven to be an effective approach for predicting the e cacy of preoperative chemotherapy in breast cancer.

show abstract

Circulating metabolites in the early stage of breast cancer were not related to cancer stage or subtypes but associated with ki67 level. Promising statistical discrimination from controls

Cited by 7 publications

References 51 publications

Small molecule metabolites: discovery of biomarkers and therapeutic targets

Small molecule metabolites: discovery of biomarkers and therapeutic targets

The Role of Amino Acids in the Diagnosis, Risk Assessment, and Treatment of Breast Cancer: A Review

Predictive analysis of breast cancer response to neoadjuvant chemotherapy through plasma metabolomics

Contact Info

Product

Resources

About